What the business is, and whether it's a good one at a fair price.
Operates a multi-specialty hospital in New Delhi under the Indraprastha Apollo Hospital brand, part of the Apollo Hospitals group. The business runs a single hospital services line, which generated Rs. 1,482.51 crore in revenue in FY26, up 9.3% from Rs. 1,356.36 crore the prior year. The cost structure is dominated by other operating expenses at 45.3% of revenue, followed by employee costs at 19.4% and materials at 17.3%; depreciation is 2.9% of revenue and capex runs at 4.0%, reflecting an asset-heavy facility. Net profit for FY26 was Rs. 183.62 crore, EPS of Rs. 20.03, and operating cash flow of Rs. 167.44 crore. The company is promoted by Apollo Hospitals Enterprise, which holds 22,917,500 equity shares, and had total assets of Rs. 991.36 crore at year-end. ICRA has reaffirmed the long-term credit rating at [ICRA]AA(Stable) on Rs. 162.50 crore of rated bank facilities.
Measured from the filed financials, judged against its Hospital peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from INDRAPRASTHA MEDICAL CORP's filed financials and exchange disclosures
INDRAPRASTHA MEDICAL CORP is a Healthcare Services company listed on NSE and BSE, trading under the symbol INDRAMEDCO.
Yes. Over the trailing twelve months INDRAPRASTHA MEDICAL CORP reported a net profit of ₹188 Cr on revenue of ₹1,524 Cr.
Yes. The dividend yield is 1.26% at the current price. It paid out 22% of its profit as dividend in FY26.
Effectively yes. It holds ₹5 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, INDRAPRASTHA MEDICAL CORP ranks 8 of 30 in Hospital — cheaper than 76% of them, against an industry median of 47.3×. This is a position, not a valuation judgement.
On a typical session INDRAPRASTHA MEDICAL CORP moves 1.38% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by INDRAPRASTHA MEDICAL CORP appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
